[Edaily Reporter Kwon Oh-seok] On the 11th, independent research firm Value Finder highlighted #BioSolution, citing key investment points such as securing sales approval in Hainan, China, for its autologous chondrocyte therapy “Cartilife,” plans for a launch in the second half of 2026, efforts to enter the mainland Chinese market, and the expansion of global business development through participation in “BioUSA 2026.”

BioSolution is a cell therapy company listed on KOSDAQ in 2018 under a technology exception, with its flagship product being the autologous cartilage cell therapy ‘Cartilife.’ Following domestic marketing approval in April 2025, the product received sales approval in China’s Hainan Medical Special Economic Zone in April 2026. The price in China has been set at approximately 42 million won, with a launch scheduled for the second half of 2026. Local sales will be handled by a partner company, and BioSolution will receive a portion of the sales price in the form of technology royalties.
The “Regulations on New Biomedical Technologies (Decree No. 818),” introduced by China in May 2026, is also considered a key variable. This system serves as a fast-track mechanism to facilitate the entry of autologous cell therapies into the mainland market and shares a similar structure to South Korea’s Advanced Regenerative Medicine Act. BioSolution is currently working with local pharmaceutical companies to utilize this system for market entry, with discussions centered on Guangzhou. As this initiative is being driven by the government, it is expected that treatments on the mainland could begin as early as 2027. In this scenario, the discount factor resulting from the “Hainan restriction” would be eliminated, and this is expected to serve as a turning point for improved performance.
In addition, the company plans to participate in Bio USA 2026, taking place in San Diego, USA, from the 22nd to the 25th of this month. The primary objective is the technology transfer (L/O) of Cartilife, and discussions on global partnerships for follow-up pipeline products such as Cartiroid and SperoCure are also expected to take place. Given that Cartilife recently applied for a Type C meeting with the FDA to proceed with its U.S. Phase 3 clinical trial, there is speculation that the technology transfer negotiations may take on greater significance.
“SperoCure,” a next-generation pipeline candidate, is a novel DMOAD (Disease-Modifying Osteoarthritis Drug) candidate designed to delay the progression of osteoarthritis itself. The efficacy of its mechanism of action has been confirmed in large-animal preclinical trials, and the company is currently awaiting IND approval for a Phase 1/2a clinical trial in Korea. Following approval, the company plans to simultaneously pursue application of the Advanced Regenerative Bio Act and preparations for U.S. clinical trials; analysts suggest that entry into advanced regulatory markets could highlight the value of technology transfer.
Researcher Lee Chung-heon explained, “CartiLife’s sales approval in Hainan marks a significant first step toward entering the Chinese market,” adding, “If the launch in Hainan is accompanied by a simultaneous entry into the mainland based on Order No. 818, the discount factors related to China will be resolved starting in 2027, allowing the company to enter a phase of substantial earnings improvement.”
He added, “If discussions on global partnerships expand following Bio USA and SperoCure’s IND approval becomes a reality, the likelihood of a revaluation of the entire pipeline’s value will also increase.”